Streetbeat News

VOR

Vor Biopharma Inc.

https://www.vorbio.com

Industry

Biotechnology

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Open

1.00

Mkt cap

68M

Volume

284K

High

1.01

P/E Ratio

-0.60

52-wk high

3.14

Low

0.94

Div yield

N/A

52-wk low

0.63

In Monday's after-market session, several health care stocks experienced significant price movements. Repare Therapeutics, Cognition Therapeutics, and Singular Genomics Sys were among the top gainers, while IGM Biosciences and Karyopharm Therapeutics saw notable declines.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 8:31 pm

Vor Bio has appointed Han Choi as its new Chief Financial Officer, effective immediately. This leadership change could influence the company's financial strategy and operations.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:06 am

Oracle shares surged by 8.8% in pre-market trading after reporting better-than-expected earnings and sales for Q1. Additionally, Oracle and Amazon's AWS launched Oracle Database@AWS, enhancing Oracle's cloud offerings. Other stocks like Silexion Therapeutics and Quoin Pharmaceuticals also saw significant pre-market movements.

Portfolio Pulse from Avi Kapoor

September 10, 2024 | 10:41 am

JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating for Vor Biopharma, maintaining a price target of $12.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 2:52 pm

Vor Biopharma Inc. (NASDAQ:VOR) announced promising clinical data from its Phase 1/2 VBP101 study for treating acute myeloid leukemia (AML) with trem-cel and Pfizer's Mylotarg. The data showed reliable engraftment and early patient benefits, leading to a 28.5% increase in VOR's stock price. Vor Bio plans to discuss a pivotal trial with the FDA and has announced a new preclinical asset, VADC45.

Portfolio Pulse from Vandana Singh

September 06, 2024 | 1:35 pm

HC Wainwright & Co. has reiterated its Buy rating for Vor Biopharma, maintaining a price target of $17.5. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 10:29 am

Argan, Inc. (NYSE:AGX) shares surged 18.4% in pre-market trading after reporting better-than-expected Q2 earnings and sales. Other notable pre-market movers include Broadcom Inc. (NASDAQ:AVGO), which fell 9.4% despite strong Q3 results, and Wheeler Real Estate Investment Trust, Inc. (NASDAQ:WHLR), which gained 175.8%.

Portfolio Pulse from Avi Kapoor

September 06, 2024 | 9:41 am

Vor Bio has released new clinical data showing the effectiveness of its shielded transplants in delivering targeted therapies. The data highlights the success of Trem-cel + Mylotarg in engraftment and patient benefit, promising results from VCAR33ALLO, and potential opportunities for VADC45 in various medical fields.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 6:44 am

Vor Bio shares have risen following the release of new clinical data that supports its strategy of using shielded transplants for targeted therapies.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 8:06 pm

Vor Bio announced promising clinical data from its Phase 1/2 VBP101 study, showing that its approach using shielded transplants with Trem-cel and Mylotarg is effective in treating relapsed/refractory AML. The study demonstrated reliable engraftment, shielding from toxicity, and patient benefits. Additionally, VCAR33ALLO showed encouraging biomarker data, and a new asset, VADC45, presents potential opportunities in oncology, gene therapy, and autoimmune disorders.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 8:03 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.